Skip to main content

Table 3 Clinical and demographic characteristics of patients receiving different CMS dosage regimens

From: Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study

Variable Colistin dosage regimen, n (%) P
1 million IU/8 h (n = 28) 2 million IU/8 h (n = 42) 3 million IU/8 h (n = 16) Other doses (n = 16)
Age (yrs) 74 (24–85) 67 (27–91) 55.5 (28–74) 73 (42–85) 0.023
N° (%) of male patients 22 (78.6) 32 (76.2) 14 (87.5) 11 (68.8) 0.64
Charlson score 4.8 ± 2.8 4.36 ± 2.6 3.7 ± 2.5 4.8 ± 2.1 0.41
N° (%) of severe sepsis 11 (39.3) 22 (52.4) 9 (56.3) 6 (37.5) 0.5
N° (%) septic shock 1 (3.6) 3 (7.1) 2 (12.5) 2 (12.5) 0.63
APACHE II 12.8 ± 6.7 11.9 ± 4.6 11.5 ± 4.45 13.7 ± 7.5 0.28
1CKD at baseline 12 (42.9) 7 (16.7) 1 (6.3) 11 (68.8) <0.0001
Colistin dose (in 2CBA) in mg/kg/day (3IBW) 1.48 ± 0.3 2.9 ± 0.37 4.38 ± 0.9 1.54 ± 0.82 <0.0001
4Cmin 0.71 (0.2-2.01) 1.14 (0.11-5) 1.84 (0.45-5.99) 1.5 (0.16-3.02) 0.003
5Cmax 0.65 (0.24-1.99) 1.13 (0.15-5) 1.84 (0.5-6.62) 1.5 (0.16-3.7) 0.001
6CMS cumulative dose 58.5 ± 50.6 111.7 ± 85.9 171.5 ± 105.7 73.9 ± 111.3 <0.0001
CMS duration treatment 20 ± 16.5 19.5 ± 15.6 19.25 ± 8 19.2 ± 19.8 0.41
Concomitant antibiotics 15 (53.6) 23 (54.8) 10 (62.5) 8 (50) 0.9
7AKI at day 7 5 (17.9) 11 (26.2) 7 (43.8) 3 (18.8) 0.25
AKI at 8EOT 14 (50) 21 (50) 9 (56.3) 6 (37.5) 0.7
Clinical response 25 (89.3) 32 (76.2) 11 (68.8) 11 (68.8) 0.3
  1. Data are n (%) except where indicated.
  2. * Median (interquartile range).
  3. ** Mean ± SD.
  4. 1CKD: chronic kidney disease. 2CBA: colistin base activity. 3IBW: ideal body weight. 4Cmin: colistin trough plasma concentrations at steady state. 5Cmax: colistin maximum plasma concentrations at steady state. 6CMS: colistinmethanesulfonate sodium 7AKI: acute kidney injury. 8EOT: end of treatment.